MTX-COVAB, a human-derived antibody with potent neutralizing activity against SARS-CoV-2 infection in vitro and in a hamster model of COVID-19
Keyword(s):
AbstractFast track microfluidic screening of the antibody repertoires of 12 convalescent COVID-19 donors comprising 2.8mio antibodies yielded MTX-COVAB, a human-derived monoclonal antibody with low picomolar neutralization IC50 of SARS-CoV-2. COVAB neutralization potency is on par with the Regeneron cocktail as demonstrated in a comparative neutralization assay. MTX-COVAB shows strong efficacy in vivo and binds to all currently identified clinically relevant variants of SARS-CoV-2. MTX-COVAB completes GMP manufacturing by the end of this year and will be tested in the clinic in March 2021.
2005 ◽
Vol 73
(10)
◽
pp. 6547-6551
◽
Keyword(s):
1994 ◽
Vol 7
(s1)
◽
pp. 556-558
◽
2005 ◽
Vol 79
(24)
◽
pp. 15238-15245
◽
Keyword(s):
1987 ◽
Vol 505
(1 Myasthenia Gr)
◽
pp. 725-727
◽